Novel Genetic Variants Expand the Functional, Molecular, and Pathological Diversity of Channelopathy.

The gene encodes Kv1.1 voltage-gated potassium channel α subunits, which are crucial for maintaining healthy neuronal firing and preventing hyperexcitability. Mutations in the gene can cause several neurological diseases and symptoms, such as episodic ataxia type 1 (EA1) and epilepsy, which may occur alone or in combination, making it challenging to establish simple genotype-phenotype correlations. Previous analyses of human variants have shown that epilepsy-linked mutations tend to cluster in regions critical for the channel's pore, whereas EA1-associated mutations are evenly distributed across the length of the protein. In this review, we examine 17 recently discovered pathogenic or likely pathogenic variants to gain new insights into the molecular genetic basis of channelopathy. We provide the first systematic breakdown of disease rates for variants in different protein domains, uncovering potential location biases that influence genotype-phenotype correlations. Our examination of the new mutations strengthens the proposed link between the pore region and epilepsy and reveals new connections between epilepsy-related variants, genetic modifiers, and respiratory dysfunction. Additionally, the new variants include the first two gain-of-function mutations ever discovered for , the first frameshift mutation, and the first mutations located in the cytoplasmic N-terminal domain, broadening the functional and molecular scope of channelopathy. Moreover, the recently identified variants highlight emerging links between and musculoskeletal abnormalities and nystagmus, conditions not typically associated with . These findings improve our understanding of channelopathy and promise to enhance personalized diagnosis and treatment for individuals with -linked disorders.